|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: NUB1 |
Gene summary for NUB1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | NUB1 | Gene ID | 51667 |
| Gene name | negative regulator of ubiquitin like proteins 1 | |
| Gene Alias | BS4 | |
| Cytomap | 7q36.1 | |
| Gene Type | protein-coding | GO ID | GO:0002376 | UniProtAcc | H3BM74 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 51667 | NUB1 | LZE2T | Human | Esophagus | ESCC | 3.51e-03 | 6.47e-01 | 0.082 |
| 51667 | NUB1 | LZE4T | Human | Esophagus | ESCC | 1.40e-05 | 2.23e-01 | 0.0811 |
| 51667 | NUB1 | LZE7T | Human | Esophagus | ESCC | 5.99e-07 | 2.20e-01 | 0.0667 |
| 51667 | NUB1 | LZE8T | Human | Esophagus | ESCC | 2.52e-10 | 3.49e-01 | 0.067 |
| 51667 | NUB1 | LZE20T | Human | Esophagus | ESCC | 1.40e-08 | 3.86e-01 | 0.0662 |
| 51667 | NUB1 | LZE24T | Human | Esophagus | ESCC | 7.96e-28 | 7.15e-01 | 0.0596 |
| 51667 | NUB1 | LZE21T | Human | Esophagus | ESCC | 1.03e-02 | 1.46e-01 | 0.0655 |
| 51667 | NUB1 | LZE6T | Human | Esophagus | ESCC | 3.23e-03 | 2.80e-01 | 0.0845 |
| 51667 | NUB1 | P1T-E | Human | Esophagus | ESCC | 1.66e-15 | 4.54e-01 | 0.0875 |
| 51667 | NUB1 | P2T-E | Human | Esophagus | ESCC | 1.76e-19 | 3.91e-01 | 0.1177 |
| 51667 | NUB1 | P4T-E | Human | Esophagus | ESCC | 1.04e-29 | 6.46e-01 | 0.1323 |
| 51667 | NUB1 | P5T-E | Human | Esophagus | ESCC | 2.65e-31 | 6.90e-01 | 0.1327 |
| 51667 | NUB1 | P8T-E | Human | Esophagus | ESCC | 1.18e-30 | 6.40e-01 | 0.0889 |
| 51667 | NUB1 | P9T-E | Human | Esophagus | ESCC | 1.20e-25 | 5.67e-01 | 0.1131 |
| 51667 | NUB1 | P10T-E | Human | Esophagus | ESCC | 3.54e-18 | 3.96e-01 | 0.116 |
| 51667 | NUB1 | P11T-E | Human | Esophagus | ESCC | 1.39e-15 | 5.21e-01 | 0.1426 |
| 51667 | NUB1 | P12T-E | Human | Esophagus | ESCC | 2.31e-35 | 6.46e-01 | 0.1122 |
| 51667 | NUB1 | P15T-E | Human | Esophagus | ESCC | 1.07e-34 | 7.17e-01 | 0.1149 |
| 51667 | NUB1 | P16T-E | Human | Esophagus | ESCC | 9.94e-19 | 3.97e-01 | 0.1153 |
| 51667 | NUB1 | P17T-E | Human | Esophagus | ESCC | 2.35e-03 | 3.39e-01 | 0.1278 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:190336234 | Oral cavity | NEOLP | regulation of cellular protein catabolic process | 64/2005 | 255/18723 | 4.83e-11 | 6.11e-09 | 64 |
| GO:004316131 | Oral cavity | NEOLP | proteasome-mediated ubiquitin-dependent protein catabolic process | 89/2005 | 412/18723 | 6.27e-11 | 7.44e-09 | 89 |
| GO:004573233 | Oral cavity | NEOLP | positive regulation of protein catabolic process | 58/2005 | 231/18723 | 3.80e-10 | 3.18e-08 | 58 |
| GO:200005834 | Oral cavity | NEOLP | regulation of ubiquitin-dependent protein catabolic process | 46/2005 | 164/18723 | 5.31e-10 | 4.20e-08 | 46 |
| GO:004586233 | Oral cavity | NEOLP | positive regulation of proteolysis | 80/2005 | 372/18723 | 7.28e-10 | 5.54e-08 | 80 |
| GO:190305034 | Oral cavity | NEOLP | regulation of proteolysis involved in cellular protein catabolic process | 54/2005 | 221/18723 | 4.32e-09 | 2.49e-07 | 54 |
| GO:003243433 | Oral cavity | NEOLP | regulation of proteasomal ubiquitin-dependent protein catabolic process | 38/2005 | 134/18723 | 1.19e-08 | 5.70e-07 | 38 |
| GO:190336433 | Oral cavity | NEOLP | positive regulation of cellular protein catabolic process | 41/2005 | 155/18723 | 2.87e-08 | 1.22e-06 | 41 |
| GO:006113632 | Oral cavity | NEOLP | regulation of proteasomal protein catabolic process | 46/2005 | 187/18723 | 4.76e-08 | 1.95e-06 | 46 |
| GO:003461231 | Oral cavity | NEOLP | response to tumor necrosis factor | 55/2005 | 253/18723 | 2.23e-07 | 7.28e-06 | 55 |
| GO:003434131 | Oral cavity | NEOLP | response to interferon-gamma | 36/2005 | 141/18723 | 5.06e-07 | 1.52e-05 | 36 |
| GO:003243632 | Oral cavity | NEOLP | positive regulation of proteasomal ubiquitin-dependent protein catabolic process | 26/2005 | 90/18723 | 1.58e-06 | 3.89e-05 | 26 |
| GO:200006032 | Oral cavity | NEOLP | positive regulation of ubiquitin-dependent protein catabolic process | 29/2005 | 107/18723 | 1.72e-06 | 4.19e-05 | 29 |
| GO:190180031 | Oral cavity | NEOLP | positive regulation of proteasomal protein catabolic process | 29/2005 | 114/18723 | 6.80e-06 | 1.36e-04 | 29 |
| GO:190305232 | Oral cavity | NEOLP | positive regulation of proteolysis involved in cellular protein catabolic process | 32/2005 | 133/18723 | 8.26e-06 | 1.60e-04 | 32 |
| GO:001049828 | Skin | cSCC | proteasomal protein catabolic process | 243/4864 | 490/18723 | 7.85e-30 | 4.10e-27 | 243 |
| GO:004217629 | Skin | cSCC | regulation of protein catabolic process | 198/4864 | 391/18723 | 6.03e-26 | 1.89e-23 | 198 |
| GO:004316128 | Skin | cSCC | proteasome-mediated ubiquitin-dependent protein catabolic process | 205/4864 | 412/18723 | 1.46e-25 | 4.16e-23 | 205 |
| GO:190336229 | Skin | cSCC | regulation of cellular protein catabolic process | 139/4864 | 255/18723 | 2.06e-22 | 4.17e-20 | 139 |
| GO:190305029 | Skin | cSCC | regulation of proteolysis involved in cellular protein catabolic process | 121/4864 | 221/18723 | 6.75e-20 | 1.01e-17 | 121 |
| Page: 1 2 3 4 5 6 7 8 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| NUB1 | SNV | Missense_Mutation | c.1849N>C | p.Asp617His | p.D617H | protein_coding | deleterious(0) | probably_damaging(0.93) | TCGA-D8-A27G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| NUB1 | SNV | Missense_Mutation | novel | c.1792N>A | p.Glu598Lys | p.E598K | protein_coding | deleterious(0) | probably_damaging(0.994) | TCGA-PL-A8LZ-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | SD | |
| NUB1 | insertion | In_Frame_Ins | novel | c.1866_1867insACACGG | p.Ile622_Ala623insThrArg | p.I622_A623insTR | protein_coding | TCGA-A8-A07F-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD | |||
| NUB1 | insertion | Frame_Shift_Ins | novel | c.1869dupA | p.Glu624ArgfsTer9 | p.E624Rfs*9 | protein_coding | TCGA-A8-A07F-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD | |||
| NUB1 | SNV | Missense_Mutation | c.683T>G | p.Val228Gly | p.V228G | protein_coding | tolerated(0.31) | benign(0.138) | TCGA-FU-A3HZ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | ||
| NUB1 | SNV | Missense_Mutation | novel | c.1870G>A | p.Glu624Lys | p.E624K | protein_coding | tolerated(0.44) | benign(0.045) | TCGA-MA-AA41-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| NUB1 | SNV | Missense_Mutation | rs373576077 | c.1118G>A | p.Arg373Gln | p.R373Q | protein_coding | tolerated(0.33) | benign(0.014) | TCGA-AA-3984-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| NUB1 | SNV | Missense_Mutation | novel | c.265T>G | p.Cys89Gly | p.C89G | protein_coding | deleterious(0.02) | benign(0.425) | TCGA-AA-A00O-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | |
| NUB1 | SNV | Missense_Mutation | rs373576077 | c.1118G>A | p.Arg373Gln | p.R373Q | protein_coding | tolerated(0.33) | benign(0.014) | TCGA-AA-A01R-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Chemotherapy | 5-fluorouracil | PD | |
| NUB1 | SNV | Missense_Mutation | rs868105409 | c.1784C>T | p.Ala595Val | p.A595V | protein_coding | tolerated(1) | possibly_damaging(0.804) | TCGA-AA-A01R-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Chemotherapy | 5-fluorouracil | PD |
| Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |